Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
for MDD) with Breakthrough Therapy designation; the MDD study (Emerge) is fully enrolled and expected to read out in late Q2 2026, Voyage (first GAD pivotal) in early Q3, and Panorama (second GAD) in H2 2026. Phase II showed a clear dose–response and selected 100 µg for Phase III, with a mean 21.9-point HAM-A reduction (7.7 placebo-adjusted) and ~50% remission at 12 weeks, plus early onset of effect and durability through 12 weeks. The company rebranded to Definium to support commercialization and is planning REMS and an eight-hour treatment-day workflow, citing potential pricing comparable to Spravato ($28k–$70k/year) if DT120 requires fewer administrations; Definium is also advancing DT402 (R-MDMA) in an early ASD proof-of-concept study. Interested in Definium Therapeutics, Inc.? Here are five stocks we like better. Definium Therapeutics (NASDAQ:DFTX) outlined its clinical pipeline and upcoming data catalysts at the Leerink Partners Global Healthcare Conference, with CEO Rob
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Announces New Employee Inducement GrantsBusiness Wire
- Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- DFTX's page on the SEC website